drugset / Trial / NCT00881062

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

NCT00881062

Phase 1 Completed 6 enrolled Repros Therapeutics Inc.
NaSingle-groupOpen-label

Summary

This study was to determine the ADME and metabolites of Proellex following a single oral dose of 25 mg.

Timeline

Start
2009-04
Primary completion
2009-05
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 25 mg Oral

Indications

No indication recorded.